CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $115.22M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.54×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
115.22MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-45.40%vs all stocks
Market Capitalization
115.22MUSDvs all stocks (USD)
Enterprise Value
-107.88MUSDvs all stocks (USD)
Forward P/E
-1.03xvs Biotechnology peers
Price to Book (MRQ)
0.5397xvs Biotechnology peers
Enterprise to EBITDA
0.8180xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-28.86%vs Biotechnology peers
Return on Equity (TTM)
-52.59%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 9, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-131.91MUSDvs all stocks (USD)
Net Income (TTM)
-126.85MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-110.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-71.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Oct 31, 2025Operating Income
-123.17MUSDvs all stocks (USD)
Pre-tax Income
-117.30MUSDFY2025 · Oct 31, 2025Income Tax Expense
0.00USDFY2025 · Oct 31, 2025Net Income
-117.30MUSDFY2025 · Oct 31, 2025EBIT
-114.31MUSDFY2025 · Oct 31, 2025EBITDA (Income Statement)
-113.80MUSDFY2025 · Oct 31, 2025Research & Development
94.48MUSDFY2025 · Oct 31, 2025Selling, General & Administrative
28.68MUSDFY2025 · Oct 31, 2025Non-operating Interest Income
9.43MUSDFY2025 · Oct 31, 2025Non-operating Interest Expense
2.99MUSDFY2025 · Oct 31, 2025EPS (Basic)
-2.29USDFY2025 · Oct 31, 2025EPS (Diluted)
-2.29USDFY2025 · Oct 31, 2025Basic Shares Outstanding
51.12MSharesFY2025 · Oct 31, 2025Diluted Shares Outstanding
51.12MSharesFY2025 · Oct 31, 2025Net Income from Continuing Operations
-117.30MUSDFY2025 · Oct 31, 2025Operating Cash Flow
-101.29MUSDFY2025 · Oct 31, 2025Free Cash Flow
-102.78MUSDFY2025 · Oct 31, 2025Cash & Cash Equivalents (End of Period)
50.15MUSDFY2025 · Oct 31, 2025Interest Paid
2.29MUSDFY2025 · Oct 31, 2025Starting Profit (CF Statement)
-117.30MUSDFY2025 · Oct 31, 2025Depreciation & Amortization
509.00KUSDFY2025 · Oct 31, 2025Stock-based Compensation
9.65MUSDFY2025 · Oct 31, 2025Other Non-cash Items
1.23MUSDFY2025 · Oct 31, 2025Change in Accounts Receivable (CF)
-595.00KUSDFY2025 · Oct 31, 2025Change in Accounts Payable (CF)
4.94MUSDFY2025 · Oct 31, 2025Change in Other Assets/Liabilities
274.00KUSDFY2025 · Oct 31, 2025Capital Expenditures
-1.49MUSDFY2025 · Oct 31, 2025Purchase of Investments
-160.84MUSDFY2025 · Oct 31, 2025Sale of Investments
137.19MUSDFY2025 · Oct 31, 2025Net Investing Cash Flow
-25.14MUSDFY2025 · Oct 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Oct 31, 2025Long-term Debt Payments
-699.00KUSDFY2025 · Oct 31, 2025Net Financing Cash Flow
-699.00KUSDFY2025 · Oct 31, 2025Shares Outstanding
66.99MSharesUpdated Jul 9, 2026Float Shares
22.49MSharesUpdated Jul 9, 2026Shares Short
1.62MSharesUpdated Jul 9, 2026Short Ratio
0.4500daysvs all stocks
Short % of Shares Outstanding
2.98%vs all stocks
% Held by Insiders
0.09%vs all stocks
% Held by Institutions
102.44%vs all stocks
Total Cash (MRQ)
258.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.86USDUpdated Jul 9, 2026Total Debt (MRQ)
33.35MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1307xvs Biotechnology peers
Current Ratio (MRQ)
12.57xvs Biotechnology peers
Book Value per Share (MRQ)
3.22USDUpdated Jul 9, 2026Total Assets
221.47MUSDvs all stocks (USD)
Total Current Assets
201.39MUSDFY2025 · Oct 31, 2025Total Liabilities
53.76MUSDFY2025 · Oct 31, 2025Total Non-current Assets
20.08MUSDFY2025 · Oct 31, 2025Total Non-current Liabilities
21.78MUSDFY2025 · Oct 31, 2025Total Current Liabilities
31.98MUSDFY2025 · Oct 31, 2025Cash & Cash Equivalents
50.15MUSDFY2025 · Oct 31, 2025Other Short-term Investments
143.58MUSDFY2025 · Oct 31, 2025Accounts Payable
6.69MUSDFY2025 · Oct 31, 2025Short-term Debt
10.02MUSDFY2025 · Oct 31, 2025Other Current Liabilities
577.00KUSDFY2025 · Oct 31, 2025Long-term Debt
21.78MUSDFY2025 · Oct 31, 2025Common Stock (Book)
513.28MUSDFY2025 · Oct 31, 2025Retained Earnings
-372.03MUSDFY2025 · Oct 31, 2025Total Shareholders' Equity
167.71MUSDvs all stocks (USD)
52-Week Low
1.40USDUpdated Jul 9, 202652-Week High
12.25USDUpdated Jul 9, 202652-Week Change
-45.40%vs all stocks
50-Day MA
4.33USDUpdated Jul 9, 2026200-Day MA
7.13USDUpdated Jul 9, 2026Avg 10-Day Volume
824.96KSharesUpdated Jul 9, 2026Avg 30-Day Volume
2.95MSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-2.18USDUpdated Jul 9, 2026Other Income / Expense
-569.00KUSDFY2025 · Oct 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.54×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.54Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 12.57Altman Z-Score: -1.85
Financial Health
Altman Z-Score -1.85: distress zoneCritical
Altman Z-Score: -1.85
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $115.22M, lower than 95% of all stocks globallySignificant
Market cap (USD): 115,221,881Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Shanghai Fudan Microelectronics Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline